Background. The goal of the present study was to assess risk factors for perinatal hepatitis C virus (HCV) transmission and the natural history of infection among HCV-infected infants.
natal HCV transmission include the presence of maternal HCV RNA at the time of delivery and maternal coinfection with HCV and HIV [2] . The data have been inconsistent regarding the role of other risk factors, including obstetrical factors and maternal serum HCV RNA titers [2] [3] [4] [5] . In addition, the timing and natural history of HCV infection among perinatally infected infants have not been fully determined [6] [7] [8] [9] [10] . To evaluate these issues, we conducted a prospective cohort study of HCV-infected women and their infants in Houston, Texas, and Honolulu, Hawaii.
SUBJECTS AND METHODS
Study population and data collection. In Houston during November 1993-July 1996, testing for antibody to HCV (anti-HCV) was offered to pregnant women attending public health clinics for prenatal care and to women with no prior prenatal care who presented for delivery at 2 county hospitals. In Honolulu, all pregnant women who received prenatal testing on Oahu during November 1994-April 1998 were offered testing. Women with positive or indeterminate anti-HCV test results were counseled regarding their test results, referred for medical evaluation, and invited to enroll in the study.
At enrollment, a questionnaire was administered to pregnant women, and a venous serum sample was collected. During hospital admission for delivery, an additional venous serum sample was collected from all mothers; colostrum samples were collected from mothers intending to breast-feed, and information regarding the pregnancy and intrapartum period was abstracted from the medical records.
Infant serum samples were collected at birth from the umbilical cord and from a peripheral venous site, as well as during well-child visits at ages 1-2, 4, 6, 9, 12, 15, 18, and 24 months. At each well-child visit, breast milk samples were collected from breast-feeding mothers, and information was obtained on breastfeeding, illnesses, and physical examination findings Among infants with evidence of HCV infection, serum samples were obtained at follow-up visits every 6 months, from ages 2 to 5 years. The study protocol was approved by the institutional review board at each participating institution and the Centers for Disease Control and Prevention, and written informed consent was obtained from all mothers before entry into the study.
Laboratory testing. Serum from HCV-infected infants that was found to be anti-HCV negative by EIA 2.0 was retested by EIA 3.0. For uninfected infants tested by EIA 2.0, the firs anti-HCV-negative sample after loss of maternal anti-HCV was retested by EIA 3.0. Serum from infected infants and peripheral venous serum collected at birth from uninfected infants that was found to be HCV RNA negative by AMPLICOR was retested by nested RT-PCR [1] .
HCV genotype was determined by direct sequencing of the NS5b region in serum from all mothers who transmitted HCV and a random selection of approximately half of HCV RNApositive mothers who did not transmit HCV [1] . Testing for serum alanine aminotransferase (ALT) levels was performed within 24 h of sample collection, using standard methods.
Testing for antibody to HIV (anti-HIV) was performed, in accordance with local standards, by EIA (HIVAB HIV-1 EIA; Abbott Laboratories) on serum from all mothers at enrollment and from infants born to HIV-infected mothers at age у15 months. Results indicating EIA-reactive serum were confi med by Western blot (Cambridge Biotech HIV-1 Western Blot Kit; Calypte Biomedical).
HCV RNA was extracted from breast milk, using the MasterPure complete DNA and RNA purificatio kit (Epicentre Technologies). Briefl , 100 mL of breast milk samples and 50 mL of RNase-free water were mixed with 300 mL of 2ϫ T and C lysis buffer containing 100 mg of proteinase K. After lysis, proteins were removed using protein precipitation reagent, the supernatant containing total nucleic acid was precipitated using isopropanol, and the pellet was washed with 75% ethanol.
Case definitions Mothers were classifie as HCV positive if their serum was found to be positive for anti-HCV by RIBA or for HCV RNA. Mothers with serum testing as RIBA indeterminate and HCV RNA negative were excluded from the analysis.
Infants were classifie as HCV infected if their serum was found to be positive for HCV RNA on at least 2 follow-up visits or was found to be anti-HCV positive at age у24 months. Infants who were persistently HCV RNA negative and who seroconverted from anti-HCV positive to anti-HCV negative during follow-up were considered to be uninfected.
Statistical analysis. Data analysis was conducted using SAS for Windows (version 6.12; SAS Institute). For univariate analyses, rates of HCV transmission were compared using Fisher's exact test. Statistical significanc of relative risk (RR) estimates was determined by calculating P values and exact 95% confi dence intervals (CIs). Multivariate analysis was conducted using logistic regression.
RESULTS

Maternal characteristics.
Overall, 75,909 pregnant women were tested for anti-HCV, and 567 (0.75%) were confi med as being HCV positive. The proportions of EIA-positive results and confi med positive results were similar at both sites. Of the 567 HCV-positive women, 332 agreed to enroll; the fina analysis included 242 women and their 244 live-born infants who completed у12 months of follow-up. Of the 242 women, 126 (52.3%) reported a history of injection drug use, 44 (19.8%) reported blood transfusion before donor screening, and 149 (61.6%) reported having been incarcerated. Frequencies of demographic characteristics, pregnancy history, and HCV risk factors among these women were similar to those among women who did not complete follow-up (table 1) .
HCV RNA was detected at enrollment or delivery in 194 (79.5%) of 242 women; the mean time from enrollment to delivery was 93 days. Of 232 women tested at both enrollment and delivery, HCV RNA was detected at both times in 179 ; this information was collected at delivery, and some women were lost to follow-up n p 36 before delivery.
(77.2%), only at delivery in 5 (2.2%), and only at enrollment in 4 (1.7%). Eleven (4.5%) of the women included in the fina analysis were anti-HIV positive; 7 (63.6%) of these women were HCV RNA positive.
Among HCV RNA-positive women, geometric mean HCV RNA levels at delivery were higher in the 7 who were HCV/HIV coinfected ( genome copies/mL) than in the 187 who 7 1.48 ϫ 10 were HIV negative ( genome copies/mL) (Wilcoxon 6 2.38 ϫ 10 ). Independently of HIV status, geometric mean HCV P ! .001 RNA levels increased between enrollment and delivery. Mean HCV RNA levels increased from to genome 6 7 7.28 ϫ 10 1.48 ϫ 10 copies/mL ( ) in HIV-positive women and from 1.63 ϫ P p .05 10 6 to genome copies/mL ( ) in HIV-negative 6 2.38 ϫ 10 P ! .001 women.
Rate of perinatal HCV transmission. Overall, 3.7% (95% CI, 1.8%-7.1%; 9/244) infants became infected with HCV. Infection developed in 0% (0/54) of infants born to mothers without detectable HCV RNA at delivery, compared with 4.6% (9/190) of infants born to HCV RNA-positive mothers (RR, undefined ). Among HCV RNA-positive mothers, the P p 0.12 rate of transmission from those who were HIV negative was 3.8% (7/182), compared with 25.0% (2/8) from those who were HIV positive (RR, 6.5 [95% CI, 1.6-26.4]); 1 of the 2 HCVinfected infants born to an HCV/HIV-coinfected mother was coinfected with HIV.
Of the 9 transmitting mothers, 8 (88.9%) were infected with genotype 1a, and 1 (11.1%) was infected with genotype 3a. Of the 107 nontransmitting HCV RNA-positive mothers tested for genotype, 68 (63.6%) had genotype 1a, 16 (15.0%) had genotype 1b, 10 (9.3%) had genotype 2b, 12 (11.2%) had genotype 3a, and 1 (0.9%) had genotype 4a. The distributions were not significantl different between the 2 groups.
Risk factors for transmission. Analysis of risk factors was restricted to the 190 infants born to mothers with detectable HCV RNA at delivery. Maternal HCV RNA levels among HCVtransmitting and -nontransmitting mothers, stratifie by maternal HIV status, are presented in figu e 1. Among HIV-negative mothers, geometric mean HCV RNA levels were higher in those who transmitted HCV ( genome copies/mL) 6 8.9 ϫ 10 than in those who did not transmit HCV ( genome 6 2.2 ϫ 10 copies/mL) (Wilcoxon ), and the risk increased with P p .02 increasing level ( , Cochran-Armitage test for trend) P p .03 (table 2) . Among HIV-infected mothers, geometric mean HCV RNA levels were lower in those who transmitted HCV (5.6 ϫ 10 6 genome copies/mL) than in those who did not transmit HCV ( genome copies/mL), but this findin was not 7 2.0 ϫ 10 statistically significan ( ) (figu e 1). P p .11 Among the HCV RNA-positive, HIV-negative mothers and their 182 infants, maternal characteristics associated with transmission in the univariate analysis included membrane rupture HCV RNA in colostrum and breast milk. The median duration of breast-feeding for the 63 women who breast-fed their infants was 1 month (mean, 4.3 months [range, 1-24 months]). HCV RNA was detected in at least 1 colostrum or breast milk sample from 19 (51.4%) of 37 HCV RNA-positive mothers who provided samples. None of these mothers transmitted HCV to their infants. Detection of HCV RNA in colostrum or breast milk was not related to HCV RNA level in maternal serum; at least 1 HCV RNA-positive breast milk or colostrum sample was detected in 5 (50%) of 10 mothers with serum HCV RNA levels р10 6 genome copies/mL, 8 (47%) of 17 mothers with levels of 10 6 -10 7 genome copies/mL, and 6 (60%) of 10 mothers with levels 110 7 genome copies/mL ( , x 2 P p .65 test for trend).
Natural history of HCV infection among infected infants. Diagnostic profile for the 9 HCV-infected infants are shown in figu e 2. HCV RNA testing of cord blood or peripheral venous serum samples collected at birth did not distinguish between infected and uninfected infants. HCV RNA was detected by AMPLICOR in cord blood samples from 5 (62.5%) of 8 infected infants and 57 (37.8%) of 151 uninfected infants.
HCV RNA was detected by nested RT-PCR (but not by AM-PLICOR) in the peripheral venous serum samples from 4 (66.7%) of 6 infected infants; 2 of these infants were born to HIV-positive mothers, and 2 were born to HIV-negative mothers. Although detection rates were lower in uninfected infants, 6 (7.4%) of 81 peripheral venous serum samples from uninfected infants were found to be HCV RNA positive by nested RT-PCR; none were HCV RNA positive in follow-up samples. All 9 infected infants were HCV RNA positive at age 2 months; in 8 infants, HCV RNA was detected by AMPLICOR, but in 1 infant HCV RNA was detected only by nested RT-PCR.
Anti-HCV profile among the 9 infected infants varied markedly (figu e 2). Three infected infants (H026, H071, and K005) were found to be anti-HCV positive by EIA and RIBA during the entire follow-up period. Another 4 infants had serologic evidence indicating a loss of passively transferred maternal antibody, followed by seroconversion to anti-HCV positivity in response to infection. One of these infants (H139) tested anti-HCV positive by EIA during follow-up but tested negative by RIBA at age 9 months; the other 3 infants (H058, H065, and H085) tested anti-HCV negative by EIA on at least 1 followup visit. Of the fina 2 infants, 1 (K048) seroconverted from anti-HCV indeterminate to anti-HCV negative between ages 15 and 24 months, and 1 (H102) seroconverted from anti-HCV positive to RIBA indeterminate between ages 48 and 60 months. Both of these seroconversions occurred after clearance of HCV RNA. In 5 infants, loss of anti-HCV or seroconversion to anti-HCV positive was preceded by EIA-positive but RIBA-indeterminate or -negative results.
None of the infected infants had any clinical signs or symptoms of hepatitis during 5 years of follow-up, although abnormal ALT activity was detected at least once in all infants (figu e 2). Three (33%) of the infected infants (H071, H102, and K048) appeared to resolve their infection and were persistently HCV RNA negative with normal ALT levels beginning at age 12-18 months (figu e 2).
Duration of anti-HCV and ALT results among uninfected infants. Among the 235 uninfected infants with у12 months of follow-up, maternal anti-HCV was detectable by EIA in 96.8% (215/222) at birth, 15.3% (30/196) at age 12 months, 4.8% (9/186) at age 15 months, 1.6% (3/190) at age 18 months, and 1.0% (2/196) at age 24 months (figu e 3). All were found to be anti-HCV negative by EIA at age 30 months. Of uninfected infants with EIA-positive results, the proportion that were RIBA positive or RIBA indeterminate declined from 100% (215/215) at birth to 73% (22/30) at age 12 months. At age 15 months, 0 of 9 uninfected infants who still tested EIA positive were RIBA positive, although 1 infant was RIBA indeterminate. At age 18 months, all 3 infants with EIA-positive results were RIBA negative. At least 1 abnormal ALT level was detected in 46 (19.3%) of 238 uninfected infants during follow-up; 32 (13.4%) had 1, 10 (4.2%) had 2, 3 (1.3%) had 3, and 1 (0.4%) had 4 abnormal ALT levels. Abnormal levels ranged from 1.02 to 4.93 (mean, 1.86) times the upper limit of normal.
DISCUSSION
The rates of HCV transmission to infants from HCV-infected, HIV-negative mothers (3.8%) and from HCV/HIV-coinfected mothers (25%) in the present study are consistent with finding from other studies [2] . Our results provide information that can be used for counseling regarding the risk of transmission through breast-feeding, the timing of follow-up to distinguish infected from uninfected infants, and the course of infection during the firs 5 years of life. The study also provides insight into risk factors that might facilitate and interventions that might prevent perinatal HCV transmission. Transmission occurred only from mothers who were HCV RNA positive, which is consistent with finding from other studies. The only 2 documented episodes of transmission from HCV RNA-negative mothers [11, 12] could be explained as resulting from the use of testing methods that were not sensitive enough to detect low levels of HCV RNA or from intermittent HCV RNA detection in an HCV-infected pregnant woman [13] . Although we detected HCV RNA intermittently among some women, 196% had consistent results when tested both prenatally and at delivery, indicating that a single HCV RNA test during pregnancy should be sufficien for diagnosis and counseling. Maternal HCV RNA testing should be required in studies of perinatal HCV transmission, and analyses should be restricted to HCV RNA-positive mothers or stratifie by HCV RNA status.
Although higher maternal viral levels increase the risk of perinatal transmission of HIV and hepatitis B virus (HBV) [14] [15] [16] , data on associations between maternal HCV RNA level and perinatal transmission have been inconsistent. In univariate analysis of HCV-positive, HIV-negative mothers, the risk of transmission has been found to increase with increasing maternal HCV RNA level, and mean levels were found to be higher in transmitting than in nontransmitting mothers. However, maternal HCV RNA level was not independently associated with transmission in multivariate analysis among HIV-negative women. A direct relationship between maternal viral level and increased transmission rates has been reported by some investigators [4, 5, 8, [17] [18] [19] [20] but not by others [10, 21, 22] . Furthermore, among the studies reporting an association, the threshold viral level associated with transmission has differed. Reasons for the inconsistencies could include the use of different methods to quantify HCV RNA levels, combining HIVnegative and HCV/HIV-coinfected women in analyses, and unrecognized statistical interactions between viral level and other factors. Given the inconsistency of results and the evidence for transmission from women with HCV RNA levels !10 6 genome copies/mL, we believe that HCV RNA level cannot be used to counsel HCV RNA-positive women about their risk for perinatal HCV transmission.
Perinatal HCV transmission could occur in utero, during the intrapartum period, or postnatally. We found no evidence for postnatal transmission, because all infected infants were HCV RNA positive by age 2 months, which is consistent with HCV exposure occurring at or before the time of delivery. This find ing contrasts with the pattern of mother-to-child HBV transmission, in which as many as 40% of infants born to HBVinfected mothers who are not infected during the intrapartum period become infected during the firs 18 months of life [23] . In addition, breast-feeding was not associated with transmission, which is consistent with finding of other studies [3, 12, 19, 22, [24] [25] [26] [27] and provides further support for recommendations that HCV-positive, HIV-negative women can safely breastfeed [28, 29] . Differentiation of in utero from intrapartum transmission is primarily based on detection of HCV RNA at the time of birth. Although HCV RNA was detected in peripheral venous serum samples from some infected infants at birth by use of nested PCR in the present study, HCV RNA was also detected in uninfected infants, suggesting that HCV RNA positivity at birth may reflec passive transferral of maternal virus rather than intrauterine transmission.
Recommendations for screening and follow-up of infants born to HCV-infected mothers include anti-HCV testing at age 115 months or nucleic acid testing on 2 occasions between ages 2 and 6 months [30] . Our finding suggest that it may be prudent to delay anti-HCV testing until age 118 months, because 2 infected infants who were anti-HCV negative at 15 months subsequently seroconverted to anti-HCV positivity, one between age 15 and 18 months and the other between age 18 and 24 months. Testing at age 118 months also eliminated all false-positive results in infants with passively acquired anti-HCV, if RIBA testing was used to verify anti-HCV EIA screening test-positive results [31] . Our finding support the recommendation for nucleic acid testing, because all infected infants were HCV RNA positive at ages 2, 4, and 6 months. Testing before age 2 months cannot be recommended, because detection of HCV RNA in both cord and peripheral venous serum samples collected at birth is likely to indicate contamination with maternal blood or passive transfer of maternal HCV RNA, rather than infant infection.
Although none of the infected infants in this study had clinical evidence of hepatitis during 5 years of follow-up, all had abnormal ALT levels at some point. These finding indicate that liver disease among HCV-infected infants is generally mild [32, 33] . The higher proportion of HCV-infected infants in the present study who resolved their infections, compared with those in follow-up studies of persons infected at older ages [5, [32] [33] [34] [35] , demonstrates the importance of follow-up testing of HCV-infected infants to determine the clinical progression of infection. Among infants born to HCV-infected, HIV-negative mothers, longer duration of membrane rupture and invasive fetal monitoring were associated with transmission. Of 2 studies that evaluated duration of membrane rupture [5, 36] , 1 found increased transmission rates associated with longer duration [5] . One study found increased transmission rates associated with fetal scalp monitoring [37] , and another found increased transmission rates associated with intrapartum exposure to maternal blood [4] . One hypothesis to explain these finding is that perinatal transmission generally occurs during the intrapartum period and is related to infant exposure to maternal genital tract secretions or blood. Although one study found no evidence of virus in genital tract secretions [38] , another detected virus in the cellular fraction of cervicovaginal secretions of 27% of infected women [39] . Both longer duration of exposure of infant mucous membranes and percutaneous inoculation of the infant could enhance transmission.
Our finding suggest that avoiding internal fetal monitoring and/ or perfoming cesarean section before or soon after membrane rupture could decrease the risk of perinatal transmission from HCV-infected mothers who were identifie prenatally. However, results from studies comparing risk for HCV transmission among infants delivered vaginally and infants delivered by cesarean section are conflictin [2, 3, 11, 12, 18, 26] . In addition, in virtually all of these studies, most study participants were HCV/HIV coinfected, coinfected and HIV-negative women were combined for analysis, and, in some instances, other potential risk factors were not accounted for. These features make it difficul to determine whether the results apply to infants born to women infected only with HCV. In addition, only 1 study differentiated elective cesarean sections performed before membrane rupture from emergency cesarean sections; that study found a lower transmission rate from mothers who delivered by elective cesarean section than from mothers who delivered by emergency cesarean section, although the analysis also included HCV/HIV-coinfected women [3] . Among HIVinfected women, elective cesarean section performed before onset of labor and rupture of membranes not only was associated with lower HIV transmission rates but also was shown, in a randomized trial, to be an effective intervention [40, 41] . In our study, no transmission occurred from mothers who delivered by elective cesarean section, but the number of such deliveries was low.
Our finding support existing recommendations to avoid internal fetal monitoring and prolonged labor after rupture of membranes in HCV-infected pregnant women [30] . Current recommendations regarding the need for cesarean section versus vaginal delivery are not based on HCV infection status. Any changes in cesarean section practices for HCVinfected pregnant women should be considered cautiously and should be based on separate studies of HCV/HIV-coinfected women and women infected only with HCV. Ideally, prospective studies should be conducted to determine whether elective cesarean section delivery reduces the risk for perinatal HCV transmission.
